WCN26-5727 CLINICAL AND LABORATORY PROFILE OF EARLY AND LATE ONSET LUPUS NEPHRITIS: A SOUTH ASIAN SINGLE-CENTRE COHORT

Wk104.The final analysis will be performed when 156 participants who receive at least 1 dose of povetacicept or tacrolimus in Ph3 complete Wk104.Safety will be evaluated.Conclusion: Povetacicept demonstrated transformational efficacy in reducing proteinuria and stabilizing renal function in pMN and was generally safe and well tolerated in Ph1/2.The OLYMPUS trial will further evaluate the efficacy and safety of povetacicept for pMN.I have potential conflict of interest to disclose.JS, RD, YC, ML and OE are employees of Vertex Pharmaceuticals and hold company stock.I did not use generative AI and AI-assisted technologies in the writing process.